Respuesta profunda y duradera en cáncer de pulmón con mutación L718Q en EGFR, adquirida después de la terapia con osimertinib
Open Access
- 5 December 2024
- journal article
- Published by Asociacion Colombiana de Hematologia y Oncologia in Revista Colombiana de Hematología y Oncología
- Vol. 11 (2) , 103-112
Abstract
Actionable mutations in the epidermal growth factor receptor (EGFR) gene are prevalent in non-small cell lung cancer (NSCLC). The advent of targeted therapy using tyrosine kinase inhibitors (TKIs) has significantly improved patient outcomes. However, the eventual development of resistance poses a substantial challenge. Molecular profiling is essential for tailoring personalized treatment strategies. Case Description: A 61-year-old female patient with NSCLC harboring the L858R mutation in EGFR was initially treated with osimertinib, achieving a complete response. Nevertheless, at 26 months, the disease progressed with the emergence of the L718Q mutation in EGFR. Osimertinib was discontinued, and a regimen of chemoimmunotherapy combined with erlotinib was initiated. The patient achieved a second complete response and remained progression-free for 14 months. Discussion: The L718Q mutation is rare and confers resistance to osimertinib. However, as demonstrated in this case, the mutation may render the tumor susceptible to alternative treatments. Several case reports suggest modest efficacy with various drug combinations, including other TKIs, chemotherapy, and antiangiogenic agents. This case represents one of the longest progression-free survival periods reported in this context. This underscores the importance of re-evaluating molecular targets upon disease progression in EGFR-mutated non-small cell lung cancer (NSCLC).Keywords
This publication has 23 references indexed in Scilit:
- Candidate mechanisms of acquired resistance to first-line osimertinib in EGFR-mutated advanced non-small cell lung cancerNature Communications, 2023
- Analysis of acquired resistance mechanisms to osimertinib in patients with EGFR-mutated advanced non-small cell lung cancer from the AURA3 trialNature Communications, 2023
- Oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-upAnnals of Oncology, 2023
- L718Q/V mutation in exon 18 of EGFR mediates resistance to osimertinib: clinical features and treatmentDiscover Oncology, 2022
- Lung Cancer in ColombiaJournal of Thoracic Oncology, 2022
- Drug Sensitivity and Allele Specificity of First-Line Osimertinib Resistance EGFR MutationsCancer Research, 2020
- Overall Survival with Osimertinib in Untreated, EGFR -Mutated Advanced NSCLCNew England Journal of Medicine, 2020
- Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLCNew England Journal of Medicine, 2018
- EGFR Mutations and Resistance to Irreversible Pyrimidine-Based EGFR InhibitorsClinical Cancer Research, 2015
- Genotyping Non-small Cell Lung Cancer (NSCLC) in Latin AmericaJournal of Thoracic Oncology, 2011